On 7th August 2026, the Department-related Parliamentary Standing Committee on Health and Family Welfare tabled its 177th report before both Houses of Parliament, titled "Prevalence of Chronic Kidney Disease in India, Prevention, Diagnosis, Treatment and Management." Headed by Rajya Sabha member Professor Ram Gopal Yadav, the report lays out 66 recommendations aimed at reshaping how India approaches one of its fastest-growing non-communicable diseases. At its core is a single, consequential proposal: mandatory kidney function testing every six months for every adult in the country aged 20 and above, alongside annual screening for those already known to be at higher risk.

This is not a minor procedural update. It represents a genuine shift in philosophy, away from a healthcare system built to treat kidney failure once it arrives, and toward one designed to catch kidney disease years before symptoms ever appear.

Why the Committee Felt This Was Necessary

The report is direct about the scale of the problem. The committee cited a pooled national CKD prevalence of approximately 13.24 percent, meaning roughly one in eight adults in India may already be living with some degree of chronic kidney disease. What makes this figure especially concerning is the disease's behaviour in its early stages. Chronic kidney disease frequently produces no noticeable symptoms until a substantial, and often irreversible, proportion of kidney function has already been lost. By the time patients present with fatigue, swelling, or other visible signs, the window for meaningful intervention has, in many cases, already narrowed considerably.

The committee also flagged that preventive nephrology, the branch of medicine focused on catching kidney disease before it progresses, has historically received far less policy and financial attention in India than the scale of the problem warrants. Its central recommendation directly addresses this gap.

What the Committee Has Recommended

The report calls for the biannual kidney function test to be made available free of cost for people below the poverty line, and at a nominal cost for those above it, delivered through the existing National Programme for Prevention and Control of Non-Communicable Diseases. For individuals already identified as high-risk, including people with diabetes or hypertension, adults over 60, those with a family history of kidney disease, people who use tobacco or carry excess weight, individuals with a prior history of kidney injury, recurrent urinary infections, or kidney stones, and those on long-term NSAID use, the committee recommends annual testing at minimum.

Crucially, the committee was specific about what this screening should actually measure. It recommended that testing for high-risk individuals include assessment of kidney function using estimated glomerular filtration rate, or eGFR, together with urine albumin or protein testing, followed by appropriate referral and follow-up. This detail matters enormously. It signals that the committee is not simply asking for more testing, but for the right combination of tests, one that looks at both how well the kidneys are currently filtering blood and whether there is early evidence of damage to the kidney's filtering units, a sign that frequently shows up before eGFR itself begins to decline.

Beyond the screening mandate itself, the report's other recommendations point to a broader institutional buildout. It calls for a dedicated National CKD Programme modelled on India's successful HIV and AIDS response, the establishment of a National CKD Registry for systematic surveillance, a district-wise CKD Performance Dashboard to track screening coverage and outcomes, and targeted screening programmes for agricultural and occupational communities in regions affected by chronic kidney disease of unknown etiology, specifically naming Andhra Pradesh, Odisha, and Karnataka, where heat stress, recurrent dehydration, and agrochemical exposure are believed to contribute to kidney damage. The committee additionally recommended strengthening nephrology services at the district level, expanding dialysis and transplantation capacity, promoting home-based peritoneal dialysis, encouraging the adoption of digital health technologies, and introducing basic kidney health education into school curricula.

Why This Recommendation Matters So Much Right Now

Recommendations of this scale are only as meaningful as the infrastructure built to carry them out, and this is precisely where the real challenge begins. Mandating biannual kidney testing for every adult above 20 means designing a screening system capable of reaching several hundred million people, twice a year, largely through primary and community health centres rather than specialist hospitals. India's existing screening apparatus under the NP-NCD, delivered through Ayushman Arogya Mandirs, already covers non-communicable disease screening for adults above 30, but extending both the age threshold and the testing frequency at this scale demands diagnostic tools that are fast, affordable, and usable without dependence on centralised laboratory infrastructure.

This is also where the committee's specific choice of tests becomes so significant. Recommending eGFR and urine albumin testing together, rather than either test in isolation, reflects a growing recognition within nephrology that these two markers catch different things at different points in the disease's progression. Relying on eGFR alone risks missing early kidney damage that has not yet affected overall filtration capacity, while relying on urine testing alone provides an incomplete picture of overall kidney function. Together, they offer a far more complete early-warning system, but only if both tests can actually be delivered at the point of care, at the volume this recommendation demands.

Where Proflo-U Fits Into This Moment

This is the exact gap that Prantae Solutions has been building toward. Proflo-U, our patented, CDSCO-approved point-of-care platform, already brings lab-grade urine albumin-to-creatinine ratio testing directly to primary and community health settings, without requiring samples to be sent to a distant laboratory or patients to wait days for results. We are now working to expand this capability further, upgrading Proflo-U to also deliver automated eGFR measurement from serum creatinine on the same platform. Once complete, this upgrade will allow a single point-of-care device to deliver both tests the parliamentary committee has explicitly recommended, uACR and eGFR, from one patient visit, at the primary care level, without the delays and infrastructure demands that centralised lab-based testing would impose at national scale.

For a screening mandate this ambitious to succeed, the tools used to deliver it need to match its scale. A national programme asking every adult over 20 to be tested twice a year cannot realistically depend on infrastructure built for occasional, symptom-triggered testing. It needs diagnostic platforms designed from the outset for high-volume, decentralised, primary-care deployment, precisely the direction Proflo-U's upcoming eGFR integration is built to support. As India's Ayushman Arogya Mandirs and district health systems begin preparing to operationalise these recommendations, a combined uACR and eGFR platform at the point of care could meaningfully close the gap between what this report asks for and what frontline health infrastructure is currently equipped to deliver.

From Recommendation to Reality

A parliamentary report, however well-researched, is only ever the starting point. Its 66 recommendations now sit with the Ministry of Health and Family Welfare, awaiting the harder work of implementation, budgeting, and rollout across a health system as vast and varied as India's. But the direction this report sets is unambiguous: the country's approach to kidney disease is meant to shift from reacting to failure toward preventing it in the first place. Whether that shift actually reaches the primary health centre in a small town or the community screening camp in a farming district will depend less on how the recommendation was written, and more on whether the diagnostic tools needed to deliver it are ready and waiting when the call finally comes.

Source: 177th Report of the Department-related Parliamentary Standing Committee on Health and Family Welfare, "Prevalence of Chronic Kidney Disease in India – Prevention, Diagnosis, Treatment and Management," presented to Parliament on 7th August 2026.